Payam Javan: On November 21, the U.S. Food and Drug Administration (FDA) announced the voluntary recall of “Umary” hyaluronic acid supplements sold on Amazon by the company MXBBB. The recalled product, a lot of 30 caplets (850 mg) with UPC code 7502265120323 and an expiration date of July 1, 2028, was found to contain undeclared active ingredients, omeprazole and diclofenac. These substances, typically used as medications for stomach acid and inflammation, respectively, can pose significant health risks when taken without medical supervision. MXBBB is arranging returns and refunds for affected consumers and has reported no adverse events related to the recall.

Health Risks of Undeclared Ingredients Omeprazole and Diclofenac
The FDA warns that diclofenac, a non-steroidal anti-inflammatory drug (NSAID), can lead to severe cardiovascular and gastrointestinal complications, including heart attacks, strokes, bleeding ulcers, and stomach perforations. Omeprazole, a proton pump inhibitor, may mask symptoms of serious stomach conditions such as ulcers or cancer and cause side effects like skin reactions and gastrointestinal discomfort. Both drugs can dangerously interact with other medications, increasing the likelihood of adverse effects. Consumers are urged to stop using the recalled product and consult healthcare professionals if they have concerns.

Recurring Issues with Umary Supplements Highlighted by FDA
This recall is part of a series of FDA actions against Umary products in 2024, including warnings in June, July, and September about the presence of undeclared ingredients like diclofenac and omeprazole in supplements by companies SoloVital and Main Products. The FDA emphasizes the risks of hidden drug ingredients, particularly in products labeled as supplements, which may exacerbate health risks when combined with other medications. Consumers are encouraged to report adverse reactions to the FDA’s MedWatch program and remain cautious about Umary products, which have faced repeated safety concerns this year.